Cyclacel Pharmaceuticals ... (CYCC)
NASDAQ: CYCC
· Real-Time Price · USD
7.85
-1.04 (-11.70%)
At close: Aug 15, 2025, 3:59 PM
8.02
2.17%
After-hours: Aug 15, 2025, 07:53 PM EDT
Cyclacel Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -1.32K | -81 | -3.05M | -1.96M | -3.26M | -2.95M | -5.27M | -6.03M | -5.45M | -5.8M | -7.42M | -5.1M | -4.58M | -4.11M | -5.29M | -4.99M | -5.13M | -3.48M |
Depreciation & Amortization | n/a | n/a | 1K | 1K | 2K | 2K | 8K | 7K | 8K | 8K | 8K | 7K | 8K | 9K | 7K | 10K | 17K | 9K |
Stock-Based Compensation | 7.00 | 1.67K | 93K | 107K | 189K | 203K | 322K | 391K | 359K | 401K | 387K | 389K | 350K | 380K | 304K | 320K | 278K | 255K |
Other Working Capital | n/a | 658K | 1.34M | -67K | 1.18M | 2.02M | 1.35M | 75K | 4.52M | -1.23M | -957K | -1.86M | 3.2M | -4.13M | -1.28M | -2.12M | 133K | -622K |
Other Non-Cash Items | 254.00 | 1.59M | n/a | -5K | -16K | -16K | 627K | -46K | -14K | -26K | 16.63M | 839K | 1.26M | -15K | n/a | n/a | n/a | n/a |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | -641K | 31K | n/a | n/a | -16.63M | -839K | -1.26M | 15K | n/a | n/a | n/a | n/a |
Change in Working Capital | n/a | -4.84M | 1.6M | -1.21M | -2K | 2.27M | 1.04M | 1.61M | 3.79M | -1.44M | 1.85M | -2.27M | 2.3M | -3.06M | 434K | -1.55M | 617K | -352K |
Operating Cash Flow | -1.06K | -3.25M | -1.36M | -3.07M | -3.08M | -483K | -3.91M | -4.04M | -1.3M | -6.86M | -5.17M | -6.97M | -1.92M | -6.78M | -4.55M | -6.21M | -4.21M | -3.57M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -6K | n/a | -7 | -3K | -4K | -2K | -9K | 62K | -78K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | -4.21M | 4.21M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a | -4.21M | 4.21M | n/a | -6K | n/a | -7 | -3K | -4K | -2K | -9K | 62K | -78K |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | -41 | n/a | n/a | n/a | n/a | n/a | -50K | -50K | -51K | -50K | -50K | -50K | -51K | -50K | -50K | -50K | -51K | -50K |
Other Financial Acitivies | 1.92K | n/a | 1.61M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Financial Cash Flow | 1.88K | 3.65M | 1.61M | -1K | 6.29M | -79K | 999K | -50K | -51K | -50K | 42K | 1.53M | 1.47M | -50K | 887K | 2.9M | -51K | 18M |
Net Cash Flow | 825.00 | 313K | 155K | -3.02M | 3.2M | -580K | -2.57M | -4.22M | -1.27M | -6.91M | -5.36M | -5.37M | -562K | -6.92M | -3.66M | -3.42M | -4.14M | 14.37M |
Free Cash Flow | -1.06K | -3.25K | -1.36M | -3.07M | -3.08M | -483K | -3.91M | -4.04M | -1.3M | -6.87M | -5.17M | -6.97M | -1.92M | -6.78M | -4.55M | -6.22M | -4.15M | -3.64M |